Podcast 89: Driving Success in Population Health with Dr. Arshad Rahim
Episode Summary
Today, John speaks with Dr. Arshad Rahim, a practicing physician and expert in population health and quality improvement at Mount Sinai Health System. He shares with us critical success factors in population health and value based care, and demonstrates his passion for driving patient quality. Dr. Rahim also speaks on the topics of physician engagement and the relationship between centralizing costs and utilization.Arshad Rahim, MD, MBA, FACP, is a practicing physician and a health economist at his core. He enjoys a track record of building innovative health care businesses, including Mount Sinai Health Partners, Healthgrades, and Sg2. As the senior medical director for population health at Mount Sinai Health System, Dr. Rahim is responsible for driving physician performance for 3000 physicians within the Mount Sinai Clinically Integrated Network, focusing on key utilization, cost, and quality metrics. Dr. Rahim has a bachelor’s degree in economics from Duke University, an MD from the University of North Carolina, and an MBA from Emory University. He completed his internal medicine residency at Yale University and Northwestern University and is an actively practicing hospitalist at the Mount Sinai Hospital.
Episode Notes
Today, John speaks with Dr. Arshad Rahim, a practicing physician and expert in population health and quality improvement at Mount Sinai Health System. He shares with us critical success factors in population health and value based care, and demonstrates his passion for driving patient quality. Dr. Rahim also speaks on the topics of physician engagement and the relationship between centralizing costs and utilization..
CONNECT WITH US:
🌐 Follow Health Care Rounds on LinkedIn
🌐 Follow Darwin Research Group on LinkedIn
📺 Watch Health Care Rounds on YouTube
⚙️ Health Care Rounds is produced by Grippi Media
Recommended Next
Darwin's Our Take: Feature: A rare FDA refusal, CDC grant cuts, and proposed ACA exchange changes

Darwin's Our Take: Lilly’s, Novo Nordisk’s share prices roller-coaster following earnings reports

Darwin's Our Take: Botox, Trulicity, Xolair among drugs selected for next round of Medicare price negotiations

Subscribe to Our Take
Sign up for Our Take Newsletter: highly curated, expert weekly strategic insights for health care executives.







